TUB-040 is under clinical development by Tubulis and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TUB-040’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TUB-040 overview
TUB-040 is under development for the treatment of solid tumors, ovarian cancer and relapsed and refractory adenocarcinoma non-small cell lung cancer. The drug candidate is a antibody-drug conjugate (ADC) being developed based on P5 conjugation platform and the Tub-tag platform. It acts by targeting NaPi2b and inhibits topoisomerase-I. It is administered through intravenous route.
Tubulis overview
Tubulis formerly known as Tubulis Technologies is a pre-start-up company that offers next-generation antibody-drug conjugates (ADCs) for the treatment of cancer. The company develops a chemo-enzymatic conjugation technique, tub-tag, for site-specific protein and antibody modifications. The development brings new flexibility in terms of drug-to-antibody ratio (DAR) by increasing ADC stability and functionality, which broadens the scope of indications treatable with ADCs. It develops technologies to deliver chemotherapeutic drugs specifically at the tumor site, which prevents side effects in healthy tissues and cells. The company is affiliated with Ludwig Maximilians University (LMU) Munich and the Leibniz-Institut fur Molekulare Pharmakologie (FMP) Berlin. Tubulis is headquartered in Berlin, Germany.
For a complete picture of TUB-040’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
